Use of Rituximab for Dermatomyositis Over Conventional Therapy: A Case Report
Case Reports in Rheumatology · 2026-01 · 2026 (1)
DOI: 10.1155/crrh/5549943 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Rheumatology, online erschienen am 11.03.2026. Verfasst von N. N. Ngcobo und 1 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We present a case of a woman hospitalized with a known history of systemic lupus erythematosus (SLE) and Type 2 diabetes mellitus. She was referred from a local public district hospital in Richards Bay (KwaZulu‐Natal, South Africa) to a tertiary/academic hospital, where her clinical assessment suggested inflammatory myositis. Initially, she presented with a progressively worsening skin rash and proximal muscle weakness. The rash began as red lesions that later healed with pigmentation, primarily in sun‐exposed areas. Two weeks after these initial symptoms, she developed scalp hair loss. Her condition eventually deteriorated to the extent that she became bed‐bound. A skin biopsy showed dermatomyositis, and a subsequent muscle biopsy confirmed the disease’s typical features. Treatment with rituximab led to improvements in both creatine kinase levels and muscle strength, suggesting its effectiveness in managing her condition.
Zitieren
APA
Ngcobo, N. N., & Mathibe, L. J. (2026). Use of Rituximab for Dermatomyositis Over Conventional Therapy: A Case Report. Case Reports in Rheumatology, 2026(1). https://doi.org/10.1155/crrh/5549943
Vancouver
Ngcobo NN, Mathibe LJ. Use of Rituximab for Dermatomyositis Over Conventional Therapy: A Case Report. Case Reports in Rheumatology. 2026;2026(1). doi:10.1155/crrh/5549943
BibTeX
@article{Ngcobo2026,
author = {Ngcobo, N. N. and Mathibe, L. J.},
title = {Use of Rituximab for Dermatomyositis Over Conventional Therapy: A Case Report},
journal = {Case Reports in Rheumatology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/crrh/5549943}
}
EUVIMED